Ivermectin, 'Wonder drug' from Japan: The human use perspective

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 87, Issue 2, 2011, Pages 13-28

  Crump, Andy ^a   Omura, Satoshi ^a  

^a KITASATO INSTITUTE   (Japan)

Author keywords

Avermectin; Drug resistance; Ivermectin; Lymphatic filariasis; Mode of action; Onchocerciasis

Indexed keywords

ANTIPARASITIC AGENT; IVERMECTIN;

CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; HUMAN; JAPAN; ONCHOCERCIASIS; REVIEW; TREATMENT OUTCOME;

ANTIPARASITIC AGENTS; DRUG RESISTANCE; HUMANS; IVERMECTIN; JAPAN; ONCHOCERCIASIS; TREATMENT OUTCOME;

ANIMALIA;

EID: 79951664903     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.87.13     Document Type: Review

References (68)

1. Ōmura, S. and Crump, A. (2005) The life and times of ivermectin: A success story. Nat. Rev. Microbiol. 2 (12), 984-989.
2. Ōmura, S. (2008) Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents 31, 91-98.
3. Campbell, W.C. (1992) The genesis of the antiparasitic drug ivermectin. In Inventive Minds (eds. Weber, R.J. and Perkins, D.N.). Oxford University Press, New York, pp. 194-214.
4. Frost, L., Reich, M.R. and Fujisaki, T. (2002) A partnership for ivermectin: Social Worlds and Boundary Objects. In Public-Private: Partnerships for Public Health (ed. Reich, M.R.). Harvard University Press, Cambridge, Mass., pp. 87-114.
5. Tavis, L.A. (1997) River Blindness: The Merck Decision to Develop and Donate MECTIZAN. In Power and Responsibility: Multinational Managers and Developing Country Concerns. University of Notre Dame Press, Indiana, pp. 87-113.
6. Thylefors, B. (2008) The Mectizan donation program. Ann. Trop. Med. Parasitol. 102 (Suppl. 1), 39-44.
7. Burg, R.W., Miller, B.M., Baker, E.E., Birnbaum, J., Currie, S.A., Hartman, R., Kong, Y.L., Monaghan, R.L., Olson, G., Putter, I., Tunac, J.B., Wallick, H., Stapley, E.O., Oiwa, R. and Ōmura, S. (1979) Avermectins, new family of potent anthelmintic agents: producing organisms and fermentation. Antimicrob. Agents Chemother. 15 (3), 361-367.
8. Miller, T.W., Chaiet, L., Cole, D.J., Cole, L.J., Flor, J.E., Goegleman, R.T., Gullo, V.P., Joshua, H., Kempf, A.J., Krellwitz, W.R., Monaghan, R.L., Ormond, R.E., Wilson, K.E., Albers-Schönberg, G. and Putter, I. (1979) Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties. Antimicrob. Agents Chemother. 15 (3), 368-371.
9. Egerton, J.R., Ostlind, D.A., Blair, L.S., Eary, C.H., Suhayda, D., Cifelli, S., Riek, R.F. and Campbell, W. (1979) Avermectins, new family of potent anthelmintic agents: efficacy of the B1A component. Antimicrob. Agents Chemother. 15 (3), 372-378.
10. Chabala, J.C., Mrozik, H., Tolman, R.L., Eskola, P., Lusi, A., Peterson, L.H., Woods, M.F., Fisher, M.H. and Campbell, W.C. (1980) Ivermectin, a new broad-spectrum antiparasitic agent. J. Med. Chem. 23, 1134-1136.
11. Campbell, W.C., Fisher, M.H., Stapley, E.O., Albers-Schönberg, G. and Jacob, T.A. (1983) Ivermectin: a potent antiparasitic agent. Science 221, 823-828.
12. Burg, R.W. and Stapley, E.O. (1989) Isolation and characterization of the producing organism. In Ivermectin and Abamectin (ed. Campbell, W.C.). Springer, New York, pp. 24-32.
13. Grisi, L., Massard, C.L., Moya-Borja, G.E. and Pereira, J.B. (2002) Impacto econômico das principais ectoparasitoses em bovinos no Brasil. Hora Veterinária 21, 8-10.
14. Ottesen, E. and Campbell, W. (1994) Ivermectin in human medicine. J. Antimicrob. Chemother. 34, 195-203.
15. Eckholm, E. (1989) Conquering an ancient scourge; river blindness. N.Y. Times Mag., 20-27 (Jan 8, 1989).
16. UNESCO (2005) World Science Report (2005) UNESCO, Paris, p. 198.
17. WHO (2010) Onchocerciasis (http://www.who.int/topics/onchocerciasis/en/).
18. Taylor, H.R., Pacqué, M., Muñoz, B. and Greene, B.M. (1990) Impact of mass treatment of onchocerciasis with ivermectin on the transmission of infection. This Week in Science 250 (5 October), 116-118.
19. WHO (1995) Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control Technical Report Series, No. 852 World Health Organization, Geneva, pp. 1-110.
20. WHO/TDR (1995) Tropical Disease Research: Progress 1975-94. WHO, Geneva, p. 95.
21. Denham, D.A. and Barrett, J. (1987) The chemotherapy of filarial nematode infections of man: aspirations and problems. In Chemotherapy of Tropical Diseases: The problem and the challenge (ed. Hooper, M.). John Wiley & Sons. Ltd., pp. 45-68.
22. Duke, B.O. (1962) Experimental transmission of Onchocerca volvulus to chimpanzees. Trans. R. Soc. Trop. Med. Hyg. 56, 271.
23. Duke, B.O. (1977) The effects of some drugs- pentamidine, stibocaptate, Hoechst 33258, F 151, compound 'E' and Nifurtimox-on Onchocerca volvulus in chimpanzees. Tropenmed. Parasitol. 28 (4), 447-455.
24. Fujisaki, T. and Reich, M. (1998) TDR's contribution to the development of ivermectin for onchocerciasis. TDR, Geneva (TDR/ER/RD/98.3).
25. WHO/TDR (1976) Participation of the Pharmaceutical sector (TDR/WP/76.30).
26. Lucas, A.O. (2002) Public-private partnerships: illustrative examples. In Public-Private Partnerships for Public Health (ed. Reich M.). Harvard University Press, Cambridge, Mass., pp. 19-39.
27. Campbell, W.C. (1991) Ivermectin as an antiparasitic agent for use in humans. Annu. Rev. Microbiol. 45, 445-474.
28. Sturchio, J.L. (1992) The Decision to Donate Mectizan: Historical Background. Merck & Co., Inc. Rahway, New Jersey, USA (unpublished document).
29. Aziz, M.A., Diallo, S., Diop, I.M., Larivière, M. and Porta, M. (1982) Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 2, 171-173.
30. Coulaud, J.P., Larivière, M., Gervais, M.C., Gaxotte, P., Aziz, A., Deluol, A.M. and Cenac, J. (1983) Treatment of human onchocerciasis with ivermectin. Bull. Soc. Pathol. Exot. Filiales 76, 681-688.
31. Telex from Robert D. Fluss of Merck & Co. Inc's Division of International Public Affairs sent to the Director of WHO/TDR, Dr Adetokunbo Lucas, on 20 June, 1986.
32. Campbell, W.C. (2010) History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. In The Chemotherapy of Parasitic Diseases: Macrocyclic Lactones. Curr. Pharm. Biotechnol. 11 (In press).
33. Awadzi, K. (1980) The chemotherapy of onchocerciasis II: Quantification of the clinical reaction to microfilaricides. Ann. Trop. Med. Parasitol. 74 (2), 189-197.
34. Dadzie, K.Y., Bird, A.C., Awadzi, K., Schulz-Key, H., Gilles, H.M. and Aziz, M.A. (1987) Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis. Br. J. Ophthalmol. 71, 78-85.
35. Larivière, M., Aziz, M., Weimann, D., Ginoux, J., Gaxotte, P., Vingtain, P., Beauvais, B., Derouin, F., Schultz-Key, H., Basset, D. and Sarfati, C. (1985) Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet 326, 174-177.
36. Diallo, S., Aziz, M.A., Ndir, O., Badiane, S., Bah, I.B. and Gaye, O. (1987) Dose-ranging study of ivermectin in the treatment of Filariasis due to Wuchereria bancrofti. Lancet (320), 1030.
37. Kumaraswami, V., Ottesen, E.A. and Vijayasekran, V. (1988) Ivermectin for treatment of Wuchereria bancrofti filariasis: efficacy and adverse reactions. JAMA 259, 3150-3153.
38. Ottesen, E.A., Kumaraswami, V. and Vijayasekran, V. (1990) A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N. Engl. J. Med. 322, 1113-1117.
39. Richards, F.O. Jr., Eberhard, M.L., Bryan, R.T., Mcneeley, D.F., Lammie, P.J., Mcneeley, M.B., Bernard, Y., Hightower, A.W. and Spencer, H.C. (1991) Comparison of high-dose ivermectin and diethylcarbamazine for activity against Bancroftian filariasis in Haiti. Am. J. Trop. Med. Hyg. 44, 3-10.
40. WHO (1997) World Health Assembly Resolution WHA 50.29 (http://www.who.int/lymphatic_filariasis/resources/WHA_50%2029.pdf).
41. Turner, M. and Schaeffer, J.M. (1989) Mode of action of ivermectin. In Ivermectin and Avermectin (ed. Campbell, W.). Springer-verlag, New York, pp. 73-88.
42. Campbell, W.C. (1985) Ivermectin: an update. Parasitol. Today 1, 10-16.
43. Omura, S. (2002) Mode of action of avermectin. In Macrolide antibiotics; Chemistry, Biology & Practice (2nd Edition) (ed. Omura, S.). Academic Press, San Diego, pp. 571-575.
44. del Mar Saez-De-Ocariz, M., McKinster, C.D., Orozco-Covarrubias, L., Tamayo-Sánchez, L. and Ruiz-Maldonaldo, R. (2002) Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin. Clin. Exp. Dermatol. 27, 264-267.
45. Maizels, R.M. and Lawrence, R.A. (1991) Immunological tolerance: the key feature in human filariasis? Parasitol. Today 7, 271-276.
46. Taylor, H.R. and Greene, B.M. (1989) The status of ivermectin in the treatment of human onchocerciasis. Am. J. Trop. Med. Hyg. 41, 460-466.
47. Plaisier, A.P., Alley, E.S., Boatin, B.A., Van Oortmarssen, G.J., Remme, H., De Vlas, S.J., Bonneux, L. and Habbema, J.D. (1995) Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J. Infect. Dis. 172, 204-210.
48. Basáñez, M.-G., Pion, S.D., Boakes, E., Filipe, J.A., Churcher, T.S. and Boussinesq, M. (2008) Effect of single-dose ivermectin on Onchocerca volvulus: s systematic review and meta-analysis. Lancet Infect. Dis. 8 (5), 310-322.
49. Duke, B.O., Soula, G., Zea-Flores, G., Bratthauer, G.L. and Doumbo, O. (1991) Migration and death of skin-dwelling Onchocerca volvulus microfilariae after treatment with ivermectin. Trop. Med. Parasitol. 42, 25-30.
50. Mackenzie, C.D., Geary, T.G. and Gerlach, J.A. (2003) Possible pathogenic pathways in the adverse clinical events seen following ivermectin administrations in onchocerciasis patients. Filaria J. 2 (Suppl. 1), S5.
51. Moreno, Y., Nabhan, J.F., Solomon, J., MacKenzie, C.D. and Geary, T.G. (2010) Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proc. Natl. Acad. Sci. USA 107 (46), 20120-20125 (doi:10.1073/ pnas.1011983107).
52. Allen, J.E., Adjei, O., Bain, O., Hoerauf, A., Hoffmann, W.H., Makepeace, B.L., Schulz-Key, H., Tanya, V.N., Trees, A.J., Wanji, S. and Taylor, D.W. (2008) Of mice, cattle and humans: The immunology and treatment of River Blindness. PLoS Negl. Trop. Dis. 2 (4), e217 (doi:10.1371.pntd.0000217).
53. Kaplan, R.M. (2004) Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol. 20, 477-481.
54. Dent, J.A. (2000) The genetics of ivermectin resistance in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 97, 2674-2679.
55. Wolstenholme, A.J. (2004) Drug resistance in veterinary helminths. Trends Parasitol. 20, 469-476.
56. Lustigman, S. and McCarter, J.P. (2007) Ivermectin resistance in Onchocerca volvulus: Toward a genetic basis. PLoS Negl. Trop. Dis. 1 (1), e76 (doi:10.1371/journal.pntd.0000076).
57. Ōmura, S. and Crump, A. (2009) Communitydirected intervention: replicating Japan's health successes in Africa? In Innovating for the health of all. Global Forum Update on Research for Health (6), Global Forum for Health Research, Geneva, pp. 87-90.
58. Geary, T.G. (2005) Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol. 21 (11), 530-532.
59. dos Santos, A.R., Falcão, C.A., Muzitano, M.F., Kaiser, C.R., Rossi-Bergmann, B. and Férézou, J.P. (2009) Ivermectin-derived leishmanicidal compounds. Bioorg. Med. Chem. 17 (2), 496-502.
60. Pitterna, T., Cassayre, J., Hüter, O.F., Jung, P.M., Maienfisch, P., Kessabi, F.M., Quaranta, L. and Tobler, H. (2009) New ventures in the chemistry of avermectins. Bioorg. Med. Chem. 17 (12), 4085-4095.
61. Moncayo, A.L., Vaca, M., Amorim, L., Rodriguez, A., Erazo, S., Oviedo, G., Quinzo, I., Padilla, M., Chico, M., Lovato, R., Gomez, E., Barreto, L.B. and Cooper, P.J. (2008) Impact of long-term treatment with ivermectin on the prevalence and intensity of soil-transmitted helminth infections. PLoS Negl. Trop. Dis. 2 (9), e293 (doi:10.1371/ journal.pntd.000293).
62. Dunne, C.L., Malone, C.J. and Whitworth, J.A. (1991) A field study of the effects of ivermectin on ectoparasites of Man. Trans. R. Soc. Trop. Med. Hyg. 85, 550-551.
63. Bockarie, M.J., Alexander, N.D., Kazura, J.W., Bockarie, F., Griffin, L. and Alpers, M.P. (2000) Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. Acta Trop. 75, 127-130.
64. Albonico, M., Crompton, D.W. and Savioli, L. (1999) Control strategies for human intestinal nematode infections. Adv. Parasitol. 42, 277-341.
65. Heukelbach, J. (2004) Ectoparasites-the underestimated realm. Lancet 363, 889-891.
66. Heukelbach, J., Winter, B., Wilcke, T., Muehlen, M., Albrecht, S., de Oliviera, F.A., Kerr-Pontes, L.R., Liesenfeld, O. and Feldmeier, H. (2004) Selective mass treatment with ivermectin to control intestinal helminthiasis and parasitic skin diseases in a severely affected population. Bull. World Health Organ. 82 (8), 559-636.
67. Editorial (2010) Nat. Rev. Microbiol. 8, 244 (doi:10.1038/nrmicro2345).
68. Speare, R. and Durrheim, D. (2004) Mass treatment with ivermectin: an underutilized public health strategy. Bull. World Health Organ. 82 (8), 559-636.